SG Americas Securities LLC Purchases Shares of 9,184 Pulmonx Co. (NASDAQ:LUNG)

SG Americas Securities LLC purchased a new stake in Pulmonx Co. (NASDAQ:LUNG) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,184 shares of the company’s stock, valued at approximately $117,000.

Other hedge funds also recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new position in Pulmonx in the first quarter valued at approximately $40,000. Ensign Peak Advisors Inc purchased a new position in Pulmonx in the third quarter valued at approximately $30,000. State of Wyoming purchased a new position in Pulmonx in the second quarter valued at approximately $30,000. Royal Bank of Canada grew its position in shares of Pulmonx by 61.3% during the second quarter. Royal Bank of Canada now owns 3,092 shares of the company’s stock worth $41,000 after acquiring an additional 1,175 shares during the last quarter. Finally, Strs Ohio purchased a new position in shares of Pulmonx during the third quarter worth approximately $85,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pulmonx

In other Pulmonx news, CEO Glendon E. French III sold 6,954 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $9.06, for a total value of $63,003.24. Following the completion of the sale, the chief executive officer now owns 1,116,758 shares of the company’s stock, valued at $10,117,827.48. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.60, for a total value of $292,000.00. Following the completion of the transaction, the chief executive officer now owns 1,121,344 shares in the company, valued at $16,371,622.40. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Glendon E. French III sold 6,954 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $9.06, for a total value of $63,003.24. Following the completion of the transaction, the chief executive officer now owns 1,116,758 shares of the company’s stock, valued at approximately $10,117,827.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,032 shares of company stock valued at $475,690. 5.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on LUNG shares. Piper Sandler restated an “overweight” rating and set a $17.00 target price on shares of Pulmonx in a research report on Wednesday, April 3rd. Stifel Nicolaus raised their target price on shares of Pulmonx from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Citigroup raised their target price on shares of Pulmonx from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $14.00 price target (down from $16.00) on shares of Pulmonx in a report on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.83.

Pulmonx Price Performance

Shares of NASDAQ LUNG opened at $7.50 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 6.50 and a quick ratio of 5.77. The stock has a fifty day moving average price of $9.90 and a 200 day moving average price of $10.81. Pulmonx Co. has a 1-year low of $7.21 and a 1-year high of $14.84. The company has a market cap of $289.05 million, a PE ratio of -4.69 and a beta of 0.60.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. Pulmonx had a negative return on equity of 46.63% and a negative net margin of 88.60%. The firm had revenue of $19.30 million during the quarter, compared to the consensus estimate of $18.24 million. During the same period last year, the company earned ($0.38) earnings per share. The company’s revenue for the quarter was up 25.3% on a year-over-year basis. Sell-side analysts forecast that Pulmonx Co. will post -1.79 EPS for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.